Teledyne FLIR Announces ION M640x Next-Gen Tactical Quadcopter
Teledyne FLIR, part of Teledyne Technologies Incorporated (NYSE:TDY), today announced the launch of the ION™ M640x tactical Unmanned Aerial System (UAS). The American designed, developed, and manufactured UAS builds on the capabilities of the ION M440 (a Blue sUAS) and will provide military and other government customers with best-in-class capabilities for their unique missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005025/en/
The Teledyne FLIR ION™ M640x tactical Unmanned Aerial System (UAS) is an American designed, developed, and manufactured UAS that will provide military and public safety users with best-in-class capabilities for their missions. The ION M640x features a 640x512 infrared sensor providing twice the resolution of similar UAS, and a Near-Infrared (NIR) laser illuminator. ION M640x includes all-new smart object tracking that enables operators to designate an object for the aircraft to detect and track while it moves. The M640x is MAVLINK compliant and interoperable with Common Ground Control Stations (C-GCS), including the U.S. Army Tactical Open Ground Station Architecture (TOGA). Easily rucksack portable at about 4 pounds, the M640x is rated for operation in demanding environments, including rain and wind. The ION M640x is evolved from the ION M440, one of the original five UAS platforms approved by the U.S. Dept. of Defense under the Blue sUAS program. (Photo: Business Wire)
“Our proven, U.S.-based engineering expertise and focus on defense and public safety markets means our customers are getting the most secure and capable UAS solutions,” said Thomas Rambo, senior director of Unmanned and Integrated Solutions at Teledyne FLIR. “The ION M640x builds on our unique position as a domestic provider of unmanned systems and sensing technology and boasts high resolution infrared imaging, smart object tracking, laser illumination, and industry-leading support and service.”
The ION M640x features a 640x512 infrared sensor providing twice the resolution of similar UAS, and a Near-Infrared (NIR) laser illuminator. The NIR illuminator enables operators to pinpoint objects of interest for increased coordination and visibility for other mission participants. ION M640x also includes all-new smart object tracking that enables operators to designate an object for the aircraft to detect and track while it moves. Other new features include an SD card to easily retrieve photos and video recorded during flight, as well as tri-band radio capabilities.
Open system architecture is another key feature of the ION M640x, and the system utilizes a high-powered discrete mission computer for advanced autonomous functions. It is also MAVLINK compliant and interoperable with Common Ground Control Stations (C-GCS), including the U.S. Army Tactical Open Ground Station Architecture (TOGA). Easily rucksack portable at about 4 pounds, the M640x is rated for operation in demanding environments, including rain and wind.
The ION M640x is evolved from the ION M440, one of the original five UAS platforms approved by the U.S. Department of Defense under the Blue sUAS program, for sale to U.S. military and federal agencies. The M440 was developed by Gainesville, Florida-based Altavian Inc., which FLIR acquired in December 2020.
Leveraging Teledyne FLIR’s longstanding reputation as a trusted provider of unmanned systems for military and public safety organizations, the ION M640x is backed by the company’s world class standards for service, training, and technical support.
About Teledyne FLIR
Teledyne FLIR, a Teledyne Technologies company, is a world leader in intelligent sensing solutions for defense and industrial applications with approximately 4,000 employees worldwide. Founded in 1978, the company creates advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. For more information, please visit www.teledyneflir.com or follow @flir.
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005025/en/
Contact information
Joe Ailinger, Jr.
Teledyne FLIR
Phone: +1 781-801-6161
Email: joe.ailinger@teledyneflir.com
Ryan Williams
Targeted Victory
Phone: +1 617-697-9072
Email: rwilliams@targetedvictory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom